×
About 7,958 results

ALLMedicine™ Myelodysplastic Syndrome Center

Research & Reviews  2,573 results

A Study of JNJ-67571244 in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
https://clinicaltrials.gov/ct2/show/NCT03915379

Dec 3rd, 2021 - This is first-in-human (FIH) Phase 1, open-label, multicenter, dose escalation study with dose expansion to evaluate the safety, tolerability, and preliminary antitumor activity of JNJ-67571244 in adult participants with relapsed or refractory acu...

Excellent Prognosis of Low-Risk Myelodysplastic Syndromes (MDS) Without Detectable Myel...
https://doi.org/10.1016/j.clml.2021.10.015
Clinical Lymphoma, Myeloma & Leukemia; Polprasert C, Niparuck P et. al.

Nov 30th, 2021 - Unexplained cytopenia (UC) and low-risk myelodysplastic syndrome (MDS) are distinguished mainly by morphologic dysplasia, which sometimes shows inter-observer discrepancy. We hypothesized that gene mutations are strong prognostic factors for these...

Comparison of flow cytometry with other modalities in the diagnosis of myelodysplastic ...
https://doi.org/10.1111/ijlh.13771
International Journal of Laboratory Hematology; Pembroke JS, Joseph JE et. al.

Nov 30th, 2021 - The myelodysplastic syndromes (MDSs) are heterogeneous myeloid malignancies, conventionally diagnosed by cytomorphology and cytogenetics, with an emerging role for flow cytometry. This study compared the performance of a 4-parameter flow cytometry...

Percutaneous left atrial appendage closure in patients with primary hemostasis disorder...
https://doi.org/10.1007/s10840-021-01073-0 10.1378/chest.09-1584 10.1097/FJC.0000000000000607 10.1111/hae.12445 10.1007/s11239-020-02097-5 10.1111/hae.12055 10.1016/j.hrcr.2019.01.014 10.1111/ejh.13296 10.1053/spen.2000.20075 10.1111/jth.12916 10.1111/j.1538-7836.2005.01204.x 10.1111/j.1538-7836.2009.03678.x 10.1056/NEJMcp1810479 10.1016/j.leukres.2005.03.004 10.1055/s-0039-1698756
Journal of Interventional Cardiac Electrophysiology : an ... Dognin N, Salaun E et. al.

Nov 26th, 2021 - We report our single-center experience with percutaneous left atrial appendage closure (LAAC) in patients with non-valvular atrial fibrillation (NVAF) and primary hemostasis disorders (HD). Consecutive patients with primary HD who underwent a perc...

Radium-223 Dichloride Long-term Follow-up Program
https://clinicaltrials.gov/ct2/show/NCT02312960

Nov 26th, 2021 - This long-term follow up study will enroll subjects who will be transferred from selected interventional, company sponsored trials with radium-223 dichloride (feeder trials). The primary objectives are to define the long term safety profile of rad...

see more →

Guidelines  2 results

Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3811170
Blood Malcovati L, Hellström-Lindberg E et. al.

Aug 28th, 2013 - Within the myelodysplastic syndrome (MDS) work package of the European LeukemiaNet, an Expert Panel was selected according to the framework elements of the National Institutes of Health Consensus Development Program. A systematic review of the lit...

Diagnostic criteria to distinguish hypocellular acute myeloid leukemia from hypocellula...
https://doi.org/10.3324/haematol.13755
Haematologica Bennett JM, Orazi A

Jan 16th, 2009 - Members of the French-American-British Cooperative Leukemia Working Group met to review cases of aplastic anemia, hypocellular myelodysplastic syndrome and hypocellular acute myeloid leukemia. Criteria were proposed and modified following three wo...

see more →

Drugs  29 results see all →

Clinicaltrials.gov  259 results

A Study of JNJ-67571244 in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
https://clinicaltrials.gov/ct2/show/NCT03915379

Dec 3rd, 2021 - This is first-in-human (FIH) Phase 1, open-label, multicenter, dose escalation study with dose expansion to evaluate the safety, tolerability, and preliminary antitumor activity of JNJ-67571244 in adult participants with relapsed or refractory acu...

Radium-223 Dichloride Long-term Follow-up Program
https://clinicaltrials.gov/ct2/show/NCT02312960

Nov 26th, 2021 - This long-term follow up study will enroll subjects who will be transferred from selected interventional, company sponsored trials with radium-223 dichloride (feeder trials). The primary objectives are to define the long term safety profile of rad...

Optimizing PTCy Dose and Timing
https://clinicaltrials.gov/ct2/show/NCT03983850

Nov 24th, 2021 - Background: Post-transplantation cyclophosphamide (PTCy) reduces rates of severe acute and chronic graft-versus-host disease (GVHD) after allogeneic hematopoietic cell transplantation (HCT) and safely facilitates human leukocyte antigen (HLA)-hapl...

Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Following Allogeneic Hematopoietic Cell Transplantation (Allo-HCT)
https://clinicaltrials.gov/ct2/show/NCT04582864

Nov 23rd, 2021 - The investigators hypothesize that MGD006 for relapsed AML following allo-HCT will be safe, tolerable and may facilitate preferential immune effector cell retargeting of leukemic cells resulting in improved patient outcomes. Furthermore, administr...

Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome
https://clinicaltrials.gov/ct2/show/NCT04401748

Nov 22nd, 2021 - Myelodysplastic Syndrome (MDS) is a group of disorders that gradually affect the ability of a person's bone marrow (semi-liquid tissue present in many bones like backbones) to produce normal blood cells. Some people with MDS have a risk of the dis...

see more →

News  315 results

Immunotherapy Shows Promise for Difficult-to-Treat HRP Ovarian Cancer
https://www.medpagetoday.com/hematologyoncology/ovariancancer/95956

Dec 1st, 2021 - A novel immunotherapy provided durable disease control in homologous repair proficient (HRP) ovarian cancer, subgroup data from a small randomized trial showed. After 3 years of follow-up, median overall survival (OS) had yet to be reached in pati...

Incorporating Mutational Panel Testing Remains Crucial in MDS
https://www.onclive.com/view/incorporating-mutational-panel-testing-remains-crucial-in-mds

Nov 24th, 2021 - Next-generation sequencing (NGS) and broad-base mutational panels can improve understanding of a patient’s disease and inform treatment decisions, therefore mutational testing should be incorporated early into the treatment of those with myelodysp...

Quizartinib/Chemo Shows Superior OS Benefit Over Chemo Alone in Newly Diagnosed FLT3-ITD+ AML
https://www.onclive.com/view/quizartinib-chemo-shows-superior-os-benefit-over-chemo-alone-in-newly-diagnosed-flt3-itd-aml

Nov 19th, 2021 - The addition of quizartinib to standard induction and consolidation chemotherapy followed by quizartinib monotherapy resulted in a statistically significant and clinically meaningful improvement in overall survival (OS) vs standard chemotherapy al...

BTK Inhibitors, PI3K Inhibitors, and CAR T-Cell Therapy Shake Up Hematologic Malignancies Armamentarium
https://www.onclive.com/view/btk-inhibitors-pi3k-inhibitors-and-car-t-cell-therapy-shake-up-hematologic-malignancies-armamentarium

Nov 15th, 2021 - BTK inhibitors, PI3K inhibitors, and CAR T-cell therapies have changed the treatment landscape of many hematologic malignancies, said Harry Paul Erba, MD, PhD, who added that the evolving paradigms underscore the need for individualized decision m...

New Trials in Leukemia: Could Your Patient Benefit?
https://www.medscape.com/viewarticle/962196

Nov 3rd, 2021 - A number of late-phase clinical trials in leukemia have opened in recent months. Maybe one of your patients could benefit from being enrolled. Adults and Children With Acute or Chronic Leukemias A phase 2 study partnering with the National Marrow ...

see more →

Patient Education  5 results see all →